PlentiPlex® MYD88

Made by PentaBase

Assist diagnosis of lymphomas

PlentiPlex® MYD88 L265P assay is intended for *in vitro* diagnosis of the leucine to proline mutation in codon 265 of the Myeloid differentiation primary response 88 protein (MYD88 L265P) in genomic DNA (gDNA) samples. The obtained results of the PlentiPlex™ MYD88 L265P assay are intended for assisting in the discrimination between patients with Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM) and non-Hodgkin lymphoma.

PlentiPlex® MYD88 has a limit of detection of 0.25%

PlentiPlex® MYD88 L265P assay combines high sensitivity with ease-of-use and is designed to work on standard real-time PCR equipment. The PlentiPlex™ MYD88 L265P assay is based on PentaBase's novel and selective INA® technologies including the use of BaseBlockers™ that suppress false positive signals from wild type (WT) templates.



PlentiPlex® MYD88 L265P assay run on a MyGo Pro qPCR instrument. Two patient samples shown, one WT and one mutated. Blue lines are reference assay and red lines are mutant specific assay.

PlentiPlex® MYD88 workflow